novo nordisk semaglutide shortage FDA ends semaglutide shortage, closing

The results of the Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) trial, the first cardiovascular outcomes trial for the short-acting GLP-1 RA lixisenatide, were also published recently [52]

Neves JS, Vasques-Nvoa F, Borges-Canha M et al (2023) Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial

GLP-1 suppresses glucagon release, slows gastric emptying, and promotes satiety signaling

Both the dosage forms of semaglutide achieve the steady-state concentration after 45 weeks of dose initiation

doi: 10.1016/j.metabol.2021.154712 [DOI] [PubMed] [Google Scholar] 28